Joan H. Schiller, MD

home / authors / joan-h-schiller-md

Articles

Putting Lung Cancer Clinical Trials Into Perspective

Jonathan E. Dowell, MD;Joan H. Schiller, MD

January 15th 2011

Ganti and colleagues have provided a comprehensive overview on recent presentations involving lung cancer.

The Benefits of Achieving Stable Disease in Advanced Lung Cancer

Tien Hoang, MD;Joan H. Schiller, MD

July 1st 2003

Dr. Kelly has written an excellentarticle demonstrating theclinical significance of achievingstable disease in advanced non–small-cell lung cancer (NSCLC)patients. This hypothesis is supportedby clinical data from two phase IItrials (Iressa Dose Evaluation in AdvancedLung Cancer [IDEAL-1 andIDEAL-2]) of the epidermal growthfactorreceptor (EGFR) inhibitor gefitinib(ZD1839, Iressa) in previouslytreated patients. She appropriatelypoints out that although tumor shrinkageis a conventionally used end pointfor cytotoxic drugs, it may not be appropriatefor the “novel” cytostaticagents. For these agents, stabilizationof disease without obvious tumorshrinkage may result in a clinicalbenefit.